Eckert & Ziegler BEBIG: First Quarter 2012 Interim Statement
(Thomson Reuters ONE) -
Regulated information
First Quarter 2012 Interim Statement
Seneffe - Belgium, May 3, 2012, Eckert & Ziegler BEBIG (Euronext: EZBG; Reuters:
EZBG.BR; Bloomberg: EZBG:BB) has announced today its Interim Statement for the
first quarter 2012 ending March 31, 2012.
The Interim Statement report including the milestones of the first quarter 2012
and a selection of consolidated key figures for the 3 months ending March
31, 2012 can be downloaded at:
http://www.bebig.eu/investor_relations/financial_reports/interim_results.html
Sales for the 1st quarter 2012 reached 7.2 million EUR, compared to 6.7 million
EUR in 1st quarter 2011, showing an increase of 6.8%. The main components were
income generated by the sales of permanent brachytherapy I-125 (Iodine-125)
radiotherapeutic implants as well as income from temporary brachytherapy
equipment, i.e. HDR equipment using Co-60 (Cobalt 60) and Ir-192 (Iridium-192)
sources (also called "afterloaders").
Earnings before interest and taxes (EBIT) have reached 0.5 million EUR in the
1st quarter 2012, versus 0.7 million EUR in the 1st quarter 2011, showing a
decrease of 22.9%.
Net profit reached 0.1 million EUR in the 1st quarter 2012, compared to the net
profit of 0.3 million EUR in the 1st quarter 2011. The main impact on the tax
position is a planned non deductible charge linked to the purchase of SonoTech.
Total equity of the group stood at 39.2 million EUR on March 31, 2012, versus
39.1 million EUR in December 31, 2011.
Cash amounted to 2.1 million EUR at the end of March 2012, versus 3.1 million
EUR in December 2011. The equity to assets ratio stood at 68.1% end of March
2012.
Eckert & Ziegler BEBIG
...Contributing to saving lives!
Eckert & Ziegler BEBIG is a European-based group, active in the medical device
sector of the healthcare industry.
Its core business is the treatment of cancer by brachytherapy, a special form of
radiotherapy. Eckert & Ziegler BEBIG is a leader in brachytherapy in Europe and
is headquartered in Belgium. It has a production facility in Germany and
subsidiaries throughout Europe, as well as in India. Eckert & Ziegler BEBIG has
also established a worldwide network of distributors and agents to support its
product line.
The company's products and equipment are intended for use by oncologists,
radiologists, urologists and medical physicists.
Eckert & Ziegler BEBIG employs more than 150 people. It has been listed on the
Euronext stock exchange since April 1997 (Euronext: EZBG; Reuters: EZBG.BR;
Bloomberg: EZBG: BB).
Contact:
Investor Relations
Tel.: +32 (0) 64 520 808
E-mail: ir(at)bebig.eu
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Eckert & Ziegler BEBIG via Thomson Reuters ONE
[HUG#1608089]
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 03.05.2012 - 01:47 Uhr
Sprache: Deutsch
News-ID 1110030
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
Seneffe
Phone:
Kategorie:
Business News
Anmerkungen:
Diese Pressemitteilung wurde bisher 63 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Eckert & Ziegler BEBIG: First Quarter 2012 Interim Statement
"
steht unter der journalistisch-redaktionellen Verantwortung von
Eckert & Ziegler BEBIG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
